Topical Senolytic Navitoclax Clears Zombie Cells, Boosts Wound Healing in Aged Mice
Researchers led by Dr. Daniel S. Roh at Boston University applied a low‑dose topical formulation of the senolytic drug navitoclax to the skin of 24‑month‑old mice. The treatment eliminated up to 15% of senescent cells, triggered a brief inflammatory response, and accelerated wound closure so that 80% of treated mice healed by day 24 versus 56% of controls. The findings suggest a new anti‑aging strategy that prepares skin for injury before it occurs.
Mediwound Ltd (MDWD) Q1 2026 Earnings Call Transcript
MedWound reported Q1 2026 revenue of $1.9 million, a sharp decline from $5.8 million a year earlier, driven primarily by a U.S. government shutdown that delayed contract awards. R&D spending jumped to $4.5 million as the company advanced the Phase III VALUE trial for...
FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
The FDA warned that unapproved compounded versions of GLP‑1 receptor agonists such as semaglutide and tirzepatide are being marketed for weight loss, posing safety and quality risks. Compounded products are not reviewed for efficacy, may be stored improperly, and have...
Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
Kailera Therapeutics reported Q1 2026 results, highlighting major clinical progress across its obesity pipeline and a successful $718.8 million IPO. The company launched a global Phase 3 KaiNETIC program for ribupatide injection, reported strong Phase 2 oral ribupatide weight‑loss data, and disclosed positive...
Agios Secures EU Marketing Authorisation for PYRUKYND in Thalassaemia
Agios Pharmaceuticals and partner Avanzanite Bioscience announced that the European Commission granted marketing authorisation for PYRUKYND (mitapivat) to treat adult patients with transfusion‑dependent and non‑transfusion‑dependent alpha‑ or beta‑thalassaemia. The decision marks the drug’s second EU indication, following its 2022 approval...
Pharmaceutical Executive Daily: FDA Approves Hepcludex
Eli Lilly announced three acquisitions valued at roughly $3 billion to broaden its pipeline beyond diabetes and obesity, targeting oncology, immunology and other growth areas. The FDA approved Hepcludex, the first U.S. therapy for chronic hepatitis delta virus infection, offering a new...
An Update on Progress at Repair Biotechnologies, Developing Means to Regress Atherosclerotic Plaque
Repair Biotechnologies announced that its lead candidate, now designated REP-0004, is a liver‑targeted mRNA lipid‑nanoparticle that produces a fusion protein to break down intracellular free cholesterol. The approach triggers a rapid, systemic pull of cholesterol from plaques, delivering dramatic regression...
Niowave, Fresh From Novartis Deal, Starts Building $75M Radioisotope Plant
Niowave announced the construction of a new $75 million actinium‑225 production facility in Lansing, Michigan, slated to begin operations in 2028. The plant will house proprietary superconducting linear accelerators and create about 70 high‑skill jobs in research, engineering, and quality assurance....
Self-Assembling Peptide Helps Liver Cancer Drugs Escape Lysosome Traps
Researchers engineered a self‑assembling peptide, RS‑FS, that remains as nanospheres in blood but converts to nanofibers inside the acidic, reducing environment of hepatocellular carcinoma lysosomes, where it damages the organelle and frees trapped drugs. In mouse models, RS‑FS combined with...
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO Transcript
Corbus Pharmaceuticals announced that it will present Phase 1/2 data for its oncology candidate CRB‑701 at the upcoming American Society of Clinical Oncology (ASCO) meeting. The data snapshot reflects an April 1 cut, and the company briefed investors via a conference call...
Arthritis Drug Tocilizumab Shows Promise for Treatment‑Resistant Depression
Researchers at the University of Bristol reported that tocilizumab, an anti‑inflammatory arthritis medication, helped 54% of participants achieve remission in a four‑week trial for treatment‑resistant depression, versus 31% on placebo. The findings suggest targeting inflammation could expand options for patients...
Compass Therapeutics to Unveil Phase 1 CTX‑8371 Data at ASCO 2026
Compass Therapeutics announced that it will present promising Phase 1 data on its bispecific antibody CTX‑8371 at the American Society of Clinical Oncology’s 2026 annual meeting. The data, derived from patients with advanced malignancies who have progressed after checkpoint‑inhibitor therapy, could...
Adcendo Inks MSD Supply Deal to Run ADC-Keytruda Combination Study
Adcendo, a Copenhagen‑based biotech, has signed a supply agreement with MSD for Keytruda to launch a Phase Ib trial of its tissue‑factor‑directed ADC ADCE‑T02 in combination with the checkpoint inhibitor. The study, slated for the second half of the year, will...
FDA Approves First Interchangeable Biosimilars to Simponi and Simponi Aria; Janssen Seeks a Preliminary Injunction to Block Their Launch
The FDA approved Accord BioPharma’s IMMGOLIS™ and IMMGOLIS INTRI™ as the first interchangeable biosimilars to Janssen’s Simponi® and Simponi ARIA® on May 15, 2026. Both products treat moderately to severely active rheumatoid arthritis, and IMMGOLIS also covers ulcerative colitis. Accord will commercialize the drugs...
New Drug Works Against Diseases Like Measles and Croup
Researchers at Georgia State University have identified GHP-88310, a new oral antiviral candidate that targets orthoparamyxoviruses such as measles and human parainfluenza virus type 3. The drug demonstrated potent, once‑daily efficacy and high tolerability in both rodent and non‑rodent animal models,...
Banner Health Report Shows Arizona Research Driving National Medical Innovation
Banner Health’s $80.5 million research enterprise reported 1,300 active clinical and translational studies in 2025, delivering an FDA‑approved device for severe mitral annular calcification and launching a $74.5 million NIH‑funded Alzheimer prevention trial in Colombia. The organization enrolled more than 89,000 participants...
Lilly Gets Back Into the Vaccine Business With New Deals
Eli Lilly & Co. announced it will acquire three clinical‑stage vaccine developers for up to $3.8 billion, marking a major re‑entry into the infectious‑disease space. The deals are financed largely by cash generated from its blockbuster obesity drugs, such as Mounjaro and...
Brazil Clears First Generic Copy of Novo Nordisk’s Ozempic Shot
Brazil’s health regulator Anvisa approved EMS’s generic semaglutide injection, Ozivy, marking the country’s first GLP‑1 copy of Novo Nordisk’s Ozempic. EMS plans to price Ozivy about 30% lower than the branded shot and expects to launch within 30 days, offering...
Beta Bionics to Launch Its First Insulin Patch Pump to Compete with Insulet
Beta Bionics announced it will debut its first insulin patch pump, called Mint, by the end of Q2 2027 pending FDA clearance. The three‑day wearable features a 200‑unit reservoir and blends reusable and disposable components, linking to the company’s adaptive dosing...
New DNA Assembly Method Bridges Design and Synthesis
A new DNA assembly method closes the gap between generative genome design and lab-scale synthesis. https://spectrum.ieee.org/faster-dna-synthesis-sidewinder?share_id=9503681
Paricalcitol Shows Promise in Metastatic Pancreatic Cancer
A small randomized trial in patients with metastatic pancreatic cancer found benefit for paricalcitol, a Vitamin D analog https://t.co/CDnIwm0xeo Good @salkinstitute explainer https://t.co/QgEKHiquIa https://t.co/m32CFTInJA
STAT+: Pharmalittle: We’re Reading About a Lilly Gene Therapy for Cholesterol, Three New Lilly Deals, and More
Eli Lilly announced that its gene‑editing therapy, acquired from Verve Therapeutics for $1 billion, lowered LDL cholesterol by 62% in a Phase 1 trial. The study reported no treatment‑related serious adverse events, paving the way for a Phase 2 trial. In parallel, Lilly...
Nanobiotix Raises $100 Million in Global Offering, ABIVAX Posts €52 Million Q1 Loss
Nanobiotix (NBTX) completed a global offering that raised $100 million after underwriters exercised their option, while ABIVAX (ABVX) posted a €52 million (≈$56.6 million) loss for Q1 2026 as R&D spending surged. The contrasting results underscore divergent trajectories among Euro‑listed biotech firms.
Biotech Surge Powers Nasdaq: AKTX Jumps 255% on KRAS Data
Akari Therapeutics (AKTX) surged more than 255% for a second straight day after preclinical data showed synergistic activity of its AKTX-101 drug with KRAS inhibition in pancreatic cancer models. The rally lifted the broader biotech sector, with Govix (GOVX) and...
Can a Chaotic FDA Still Deliver on Faster Drug Development?
Recent leadership upheaval at the FDA, including the departure of Commissioner Martin Makary, has sparked concerns about the agency’s ability to maintain momentum on accelerating early‑stage clinical trials in the United States. Nonetheless, industry insiders like Parexel’s Tala Fakhouri argue...
AstraZeneca, Daiichi Sankyo Win EU CHMP Nod for Enhertu in HER2 Tumors
AstraZeneca and Daiichi Sankyo received a positive opinion from the European Medicines Agency's CHMP for Enhertu, expanding the antibody‑drug conjugate to HER2‑positive solid tumours after prior therapy. The endorsement is based on subgroup analyses from Phase II DESTINY trials that showed...
Strep A Vaccine Gets $140mn Backing
Global health philanthropists have launched a $140 million fund, led by Coefficient Giving and donors such as Dustin Moskovitz, to accelerate development of a Group A Streptococcus (Strep A) vaccine. The fund aims to double the pipeline of vaccine candidates and bring at...
Two Decades of Evolving ASCO Clinical Trial Trends
Trends and characteristics of clinical trials presented in ASCO plenary sessions (2011–2025) - Overheu #ASCO26 Abstract # 11024, Poster Bd # 7 https://t.co/JYI0LY7FbU #ClinicalTrials #ctsm @ASCO
Ivonescimab Shows
#ASCO26 LBA4 - Zhiwei - Ivonescimab + chemo vs tislelizumab + chemo 1L sq NSCLC - Ph3 HARMONi-6 [May 31, 2026] Zhiwei et al. https://t.co/oWEeVo2oyq #NCT05840016 #lcsm #ImmunoOnc
Merz Therapeutics and Kvvit Partner to Advance Inbrija in Mainland China, Hong Kong and Macao
Merz Therapeutics has licensed its inhaled levodopa product Inbrija to Chinese biotech Kvvit for exclusive commercialization in mainland China, Hong Kong and Macao. The agreement assigns Merz responsibility for drug supply, global quality oversight and holding the overseas registration certificate,...
Len
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol https://t.co/hXxlFINejC #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm https://t.co/Gx8qHe4PLo
STAT+: Eli Lilly to Buy Three Small Vaccine Developers
Eli Lilly announced it will acquire three early‑ and mid‑stage vaccine developers—Curevo, LimmaTech Biologics and Vaccine Company—for a combined price of nearly $4 billion. The deals expand Lilly’s pipeline into vaccines targeting pathogens that cause long‑term health complications. Funding comes from the...
Arthrosi Drug Trial in Gout Delivers for New Owner Sobi
Swedish biotech Sobi’s $1.5 billion acquisition of Arthrosi is yielding results as its gout drug pozdeutinurad met primary goals in the phase 3 REDUCE‑2 trial. The URAT1 inhibitor lowered serum uric acid to ≤6 mg/dl in 69.2% of patients at a 75 mg dose...
Nanoscale Drug Delivery Systems for Ovarian Cancer: Targeting Strategies, Theranostic Platforms, and Translational Challenges
A new review maps the evolution of nanoscale drug delivery systems (DDS) for ovarian cancer, shifting focus from blunt chemotherapy to precision nanomedicine. It outlines three core design strategies—active targeting, microenvironment‑responsive release, and theranostic integration—across carriers such as liposomes, polymeric...
EU Approves Wegovy 7.2 Mg Pen Amid Expert Warnings of Bone Loss
The European Medicines Agency’s CHMP has recommended approval of Novo Nordisk’s Wegovy 7.2 mg single‑dose pen, which delivered a 20.7% average weight loss in trials. At the same time, orthopedic experts caution that rapid weight loss from GLP‑1 drugs can erode muscle...
A Photothermally Triggered Cascade Nanodelivery Platform for On‐Demand Nitric Oxide Release in Targeted Hepatocellular Carcinoma Therapy
Researchers have engineered a gold nanocage‑based nanoplatform (GIL9R) that co‑encapsulates indocyanine green and L‑arginine and is surface‑functionalized with the HCC‑targeting peptide 9R‑P201. Upon near‑infrared irradiation, the platform produces localized heat, reactive oxygen species, and catalyzes nitric‑oxide release, delivering combined photothermal,...
AstraZeneca Secures Positive EU CHMP Opinion for Camizestrant Combo in Advanced Breast Cancer
AstraZeneca announced that the European Medicines Agency’s CHMP has issued a positive opinion on camizestrant combined with a CDK4/6 inhibitor for ER‑positive, HER2‑negative advanced breast cancer with ESR1 mutations. The Phase III SERENA‑6 trial showed a 56% reduction in disease progression...
Will Lab-Grown Sperm Let Infertile Men Have Children of Their Own?
A US start‑up, Paterna Biosciences, says it can turn testicular stem cells into sperm in the lab, potentially offering a solution for men whose infertility cannot be treated with existing methods. The company claims the technique could enable almost all...
Northern Irish Health Tech Expands in the US After FDA Win
Neurovalens, a Belfast‑based health‑tech startup, received FDA De Novo clearance for its Modius Spero wearable that treats PTSD with low‑level electrical stimulation. The company will begin prescribing the device to U.S. veterans through the Department of Veterans Affairs in July, marking...
Pierre Fabre’s Braftovi Gains CHMP Positive Opinion for mCRC
The European Medicines Agency’s CHMP issued a positive opinion on Pierre Fabre’s Braftovi (encorafenib) combined with cetuximab and Folfox as a first‑line treatment for metastatic colorectal cancer (mCRC) harboring BRAFV600E mutations. The Phase III BREAKWATER trial demonstrated a 51% reduction in...
Pierre Fabre’s Braftovi Gains CHMP Positive Opinion for mCRC
The European Medicines Agency’s CHMP issued a positive opinion for Pierre Fabre’s Braftovi (encorafenib) combined with cetuximab and Folfox as a first‑line treatment of BRAFV600E‑mutant metastatic colorectal cancer. The Phase III BREAKWATER trial showed a 51 % reduction in death risk, extending median...
The European CDMO Model, Powering Biologics Innovation
European contract development and manufacturing organisations (CDMOs) are becoming pivotal as biologics grow in complexity, and 3PBIOVIAN exemplifies this shift with a pan‑European, end‑to‑end model. The company operates GMP‑certified facilities in Pamplona, Spain, and Turku, Finland, offering microbial, mammalian, viral...
Does Ceramide Lipid Metabolism Affect Response to Prostate Cancer Drugs?
Researchers discovered that ceramide lipid metabolism varies by genetic ancestry and influences response to androgen‑receptor pathway inhibitors in metastatic castration‑resistant prostate cancer. Black patients entered treatment with lower total ceramides but higher C24‑to‑C16 ratios, a pattern that flipped during therapy....
AstraZeneca Receives the CHMP Positive Opinion for Camizestrant to Treat Advanced Breast Cancer
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on AstraZeneca’s oral selective estrogen receptor degrader camizestrant, to be used with a CDK4/6 inhibitor for ER‑positive, HER2‑negative advanced breast cancer harboring ESR1 mutations....
Amgen Drug Reviewed Amid Deaths
Amgen’s rare‑disease drug Tavneos (avacopan) resumed sales in Japan after a new warning label was added following 20 reported deaths linked to liver injury. The drug, acquired when Amgen bought ChemoCentryx in 2022, generated $459 million in 2025 sales. In the...
Follow the Money: AI Drug Design Engine, Treating Multiple Myeloma, Quantum Healthcare Platform
Isomorphic Labs closed a $2.1 billion Series B to scale its AI drug‑design engine, while CellCentric secured $220 million to push its oral myeloma candidate, inobrodib, into Phase 3 trials. NVision raised $55 million Series B to merge quantum computing with its POLARIS MRI platform, aiming...
REGENXBIO, Novartis, Dyne Near FDA Submissions in Muscular Dystrophies
A wave of near‑term regulatory activity is reshaping the muscular dystrophy landscape. REGENXBIO reported mixed Phase 3 data for its gene therapy RGX‑202, achieving 93% microdystrophin expression but raising safety flags, while targeting a 2027 launch. Novartis’ $12 billion acquisition of Avidity...
Can Fast, Nimble Clinical Trials Deliver a Drug to Halt the New Ebola Outbreak?
The World Health Organization and African health agencies have launched an adaptive, randomized clinical trial in the Democratic Republic of the Congo to evaluate two therapies—remdesivir and the experimental antibody cocktail MBP134—against the Bundibugyo strain of Ebola. The protocol draws...
Noxopharm Studies Confirm Cancer-Fighting Potential of Sofra Platform
Australian biotech Noxopharm announced new data on its Sofra platform, a TLR8‑activating oligonucleotide technology that could enhance cancer immunotherapy. Preclinical studies demonstrated up to a 200‑fold boost in TLR8 activity in human skin biopsies and nearly three‑fold activation in animal...
Gilead's Trodelvy Wins CHMP Positive Opinion for First‑Line Metastatic Triple‑Negative Breast Cancer
The European Medicines Agency’s CHMP has issued a positive opinion on Gilead’s Trodelvy for first‑line treatment of metastatic triple‑negative breast cancer (mTNBC) in patients who cannot receive PD‑(L)1 inhibitors. The recommendation follows the ASCENT‑03 trial, which showed a 38% reduction...